Ireland
--:--IST
Recruiting Not applicable

Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy

NCT06027242 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2023-02-21
Last updated
2025-12-23

Condition(s) studied

Gastric CancerImmunonutritionGastrostomy

Investigational drug(s) / intervention(s)

oral glutamineMaltodextrin

oral glutamine: 10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding

Maltodextrin: Maltodextrin

Study summary

Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * adult gastric cancer receiving gastrectomy Exclusion Criteria: * Hepatic insufficiency * Renal insufficiency * can not tolerate oral or enteral feeding 7 days after gastrectomy * can not receive computed tomograph * can not waer the wearable devices

Primary outcome measure(s)

  • Change of area of psoas muscle — 84 days after gastrectomy
    area od psoas muscle on the CT scan

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06027242 on ClinicalTrials.gov ↗ ← All trials in Taiwan